Crossmark

An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis

Crossref DOI link: https://doi.org/10.1186/s41100-022-00409-4

Published Online: 2022-06-11

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ugamura, Daisuke

Hosojima, Michihiro https://orcid.org/0000-0002-2750-735X
Kabasawa, Hideyuki

Tanabe, Naohito

Yoshizawa, Yuta

Suzuki, Yoshiki

Saito, Akihiko

Narita, Ichiei
License Information

Text and Data Mining valid from 2022-06-11

Version of Record valid from 2022-06-11
More Information

Article History

Received: 16 December 2021

Accepted: 1 May 2022

First Online: 11 June 2022

Declarations

:

: The Ethics Committee of the Niigata University School of Medicine approved the study (approval numbers: 2015-2573). Written informed consent was obtained from each participant.

: Not applicable.

: MH and AS received lecture fees and donations for research from Eli Lilly Japan K. K. and Sumitomo Dainippon Pharma Co., Ltd.

Document is current

Any future updates will be listed below